Clinical Trial Update: Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 [Phase 3]

View source ↗

Summary

Phase 3 trial update on safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 with immunobridging to 18-49; the study is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• VAX-31 (31-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Vaxcyte, Inc. | Conditions: Pneumococcal Vaccines | Phase 3 | Status: ACTIVE_NOT_RECRUITING